Autoinflammatory & rare systemic diseases
Tofacitinib for the treatment of recurrent IgG4-related disease: clinical experience in 7 patients
Authors' conclusion
Tofacitinib is effective and safe for the management of recurrent IgG4-RD, with the additional benefit of reducing GC dependence.
Study context
- Population
- Patients with recurrent IgG4-related disease (IgG4-RD) meeting the 2019 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria, Rheumatology Department of Peking University People's Hospital; aged 33–70 years, mean disease duration 45 months (range 18–84)
- Participants
- 7 patients
- Outcome
- Treatment response (CR, partial response (PR) or relapse), assessed by IgG4-RD RI, PGA and serum IgG4 levels
Methodological detailscase series, single-centre, Clinical data recorded at baseline, 1 month, 3 months, and every 3 months thereafter
- Case series
- Single-centre
- Clinical data recorded at baseline, 1 month, 3 months, and every 3 months thereafter
Main finding
As reported in the abstract
Treatment response
Complete response (CR)
6
Relapse
1
Observational data: associations, not effects.
Further findings
IgG4-RD RI score reduction vs baseline · 1, 3 and 6 months
- Reduction at 1 month
- P = 0.017
- Reduction at 3 months
- P = 0.018
- Reduction at 6 months
- P = 0.043
Physician global assessment (PGA) score reduction vs baseline · 1, 3 and 6 months
- Reduction at 1 month
- P = 0.017
- Reduction at 3 months
- P = 0.018
- Reduction at 6 months
- P = 0.042
Serum IgG4 level decrease · 3 and 6 months
- Decrease at 3 months
- P = 0.028
- Decrease at 6 months
- P = 0.043
GC dosage · within 6 months
- Reduced GC dosage to ≤5 mg/day (prednisone equivalent)
- 4 of 7
- Discontinued glucocorticoids (GCs) during follow-up
- 2
Safety
| Outcome | Values |
|---|---|
| Mild herpes zoster | Tofacitinib 1 events |
Serious AEs
- No serious AEs reported
Tolerability
- Tofacitinib was well tolerated
Original publication
Tofacitinib for the treatment of recurrent IgG4-related disease: clinical experience in 7 patients. Clin Exp Rheumatol. Published 8 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →